Definition

MINOCA = Clinical evidence of myocardial infarction (MI) (troponin rise/fall + ischemic symptoms, ECG/imaging changes, or wall motion abnormalities) without significant obstructive coronary artery disease on angiography (no stenosis ≥50%).

---

🔹 Diagnostic Criteria (per ESC/ACC)

1. Fulfills the Fourth Universal Definition of MI.
2. No coronary artery stenosis ≥50% on angiography.
3. No other obvious cause for troponin elevation (like sepsis, PE, myocarditis).

---

🔹 Pathophysiology / Mechanisms

MINOCA is not one disease, but a syndrome with multiple mechanisms:

• Plaque-related causes
  • Plaque rupture/erosion with transient thrombosis
  • Coronary artery spasm
• Non-plaque coronary causes
  • Spontaneous coronary artery dissection (SCAD)
  • Coronary embolism/thrombosis
  • Microvascular dysfunction
• Non-coronary cardiac causes
  • Myocarditis
  • Takotsubo (stress) cardiomyopathy

---

🔹 Investigations

After angiography rules out obstructive CAD, further tests help identify the underlying cause:

• Cardiac MRI (CMR): distinguishes infarction vs. myocarditis vs. Takotsubo.
• IVUS / OCT (intravascular imaging): detects plaque rupture/erosion, SCAD.
• Coronary vasospasm testing (acetylcholine, ergonovine).
• Blood work: thrombophilia, autoimmune disorders.

---

🔹 Management

Treatment depends on the identified mechanism:

• If atherosclerotic mechanism suspected → treat like conventional MI (statins, ACEi/ARB, β-blockers, antiplatelets).
• Coronary vasospasm → calcium channel blockers, nitrates.
• SCAD → conservative management preferred unless ongoing ischemia.
• Takotsubo / myocarditis → supportive therapy (not ACS protocol).

⚠️ Routine dual antiplatelet therapy (DAPT) in all MINOCA patients is not recommended unless plaque disruption is proven.

---

🔹 Prognosis

• MINOCA is not benign.
• 1-year mortality ~3–4%, rehospitalization and recurrent MI risk present.
• Prognosis is better than obstructive MI but worse than the general population.

---

🔹 Key Points Summary (Quick Review)

1. MINOCA = MI with ≤50% stenosis on angiography.
2. Occurs in 5–10% of all MI cases.
3. Causes: plaque rupture/erosion, spasm, SCAD, embolism, microvascular dysfunction, myocarditis, Takotsubo.
4. Diagnosis: Exclude mimics + advanced imaging (CMR, IVUS/OCT).
5. Management: Cause-directed; not one-size-fits-all ACS therapy.
6. Prognosis: intermediate – worse than healthy, better than obstructive MI.

Definition

MINOCA = Clinical evidence of myocardial infarction (MI) (troponin rise/fall + ischemic symptoms, ECG/imaging changes, or wall motion abnormalities) without significant obstructive coronary artery disease on angiography (no stenosis ≥50%).

---

🔹 Diagnostic Criteria (per ESC/ACC)

1. Fulfills the Fourth Universal Definition of MI.
2. No coronary artery stenosis ≥50% on angiography.
3. No other obvious cause for troponin elevation (like sepsis, PE, myocarditis).

---

🔹 Pathophysiology / Mechanisms

MINOCA is not one disease, but a syndrome with multiple mechanisms:

• Plaque-related causes
  • Plaque rupture/erosion with transient thrombosis
  • Coronary artery spasm
• Non-plaque coronary causes
  • Spontaneous coronary artery dissection (SCAD)
  • Coronary embolism/thrombosis
  • Microvascular dysfunction
• Non-coronary cardiac causes
  • Myocarditis
  • Takotsubo (stress) cardiomyopathy

---

🔹 Investigations

After angiography rules out obstructive CAD, further tests help identify the underlying cause:

• Cardiac MRI (CMR): distinguishes infarction vs. myocarditis vs. Takotsubo.
• IVUS / OCT (intravascular imaging): detects plaque rupture/erosion, SCAD.
• Coronary vasospasm testing (acetylcholine, ergonovine).
• Blood work: thrombophilia, autoimmune disorders.

---

🔹 Management

Treatment depends on the identified mechanism:

• If atherosclerotic mechanism suspected → treat like conventional MI (statins, ACEi/ARB, β-blockers, antiplatelets).
• Coronary vasospasm → calcium channel blockers, nitrates.
• SCAD → conservative management preferred unless ongoing ischemia.
• Takotsubo / myocarditis → supportive therapy (not ACS protocol).

⚠️ Routine dual antiplatelet therapy (DAPT) in all MINOCA patients is not recommended unless plaque disruption is proven.

---

🔹 Prognosis

• MINOCA is not benign.
• 1-year mortality ~3–4%, rehospitalization and recurrent MI risk present.
• Prognosis is better than obstructive MI but worse than the general population.

---

🔹 Key Points Summary (Quick Review)

1. MINOCA = MI with ≤50% stenosis on angiography.
2. Occurs in 5–10% of all MI cases.
3. Causes: plaque rupture/erosion, spasm, SCAD, embolism, microvascular dysfunction, myocarditis, Takotsubo.
4. Diagnosis: Exclude mimics + advanced imaging (CMR, IVUS/OCT).
5. Management: Cause-directed; not one-size-fits-all ACS therapy.
6. Prognosis: intermediate – worse than healthy, better than obstructive MI.

---

Clinical Assessment of MINOCA

1. Initial Clinical Presentation

• Similar to classic MI:
  • Chest pain / pressure (often ischemic pattern)
  • Dyspnea, diaphoresis, palpitations, syncope
  • ECG changes (ST elevation/depression, T-wave inversion, LBBB)
  • Troponin rise/fall consistent with myocardial injury

👉 At this stage, the patient is managed as an acute coronary syndrome (ACS).

---

2. Coronary Angiography

• Reveals no obstructive CAD (≤50% stenosis).
• Confirms MINOCA suspicion.

---

3. Systematic Evaluation

Since MINOCA is a syndrome, clinical assessment must rule out alternative causes of troponin elevation.

A. Exclude Non-Ischemic Mimics

• Myocarditis (viral, autoimmune, etc.)
• Takotsubo syndrome
• Pulmonary embolism
• Sepsis, renal failure, tachyarrhythmia

B. Identify Coronary Causes

• Plaque disruption (rupture/erosion, detected by IVUS/OCT)
• Coronary vasospasm (provocative testing if safe)
• Spontaneous coronary artery dissection (SCAD)
• Coronary embolism/thrombosis
• Microvascular dysfunction

---

4. Investigations to Refine Diagnosis

• Cardiac MRI (CMR):
  • Differentiates MI vs. myocarditis vs. Takotsubo.
  • Detects late gadolinium enhancement patterns.
• IVUS / OCT:
  • Detects hidden plaque rupture, erosion, SCAD.
• Echocardiography:
  • Wall motion abnormalities, Takotsubo patterns.
• Blood work:
  • Thrombophilia screen, autoimmune panel, viral markers.

---

5. Risk Stratification

• Assess cardiovascular risk factors (HTN, DM, smoking, dyslipidemia).
• Look for triggers (emotional stress, postpartum, vasospastic angina, connective tissue disorders).

---

🔹 Bedside Clinical Checklist (Practical)

✅ Symptoms consistent with ACS
✅ ECG showing ischemic changes
✅ Troponin rise/fall
✅ Angiography with ≤50% stenosis
✅ Rule out systemic causes of troponin elevation
✅ Use CMR, IVUS/OCT for etiology
✅ Decide treatment based on underlying cause

---

📌 Key Point:
The clinical assessment of MINOCA is not finished at angiography — it requires a multi-modality approach (history, labs, imaging, intravascular assessment) to uncover the hidden mechanism and tailor therapy.

Point	Clinical Assessment Step	Details
1	Definition	MI (per universal definition) with ≤50% stenosis on angiography.
2	Initial Symptoms	Chest pain, dyspnea, diaphoresis, palpitations, syncope.
3	ECG Findings	ST-elevation, ST-depression, T-wave inversion, or LBBB.
4	Biomarkers	Troponin rise/fall consistent with myocardial injury.
5	First Step	Manage initially as ACS until angiography.
6	Coronary Angiography	Shows no obstructive CAD (≤50% stenosis).
7	Key Concept	MINOCA is a working diagnosis, not the final diagnosis.
8	Exclude Non-Ischemic Causes	Myocarditis, Takotsubo, PE, sepsis, tachyarrhythmia.
9	Myocarditis Suspicion	Viral prodrome, fever, diffuse ST changes.
10	Takotsubo Suspicion	Post-stress trigger, apical ballooning pattern on echo.
11	Pulmonary Embolism Suspicion	Dyspnea, hypoxemia, right heart strain.
12	Coronary Causes	Plaque rupture, spasm, SCAD, embolism, microvascular dysfunction.
13	Plaque Rupture/Erosion	Often detected only with OCT/IVUS.
14	SCAD	Common in young women, postpartum, associated with fibromuscular dysplasia.
15	Coronary Spasm	May require acetylcholine or ergonovine provocation testing.
16	Coronary Embolism	From AF, endocarditis, prosthetic valves, hypercoagulable states.
17	Microvascular Dysfunction	Suspect if persistent angina with normal coronaries.
18	Imaging: Cardiac MRI (CMR)	Differentiates MI from myocarditis and Takotsubo.
19	Echocardiography	Useful for wall motion abnormalities, LV function, Takotsubo.
20	Risk Stratification	Assess cardiovascular risk factors and triggers (stress, postpartum, autoimmune).

---

Short Q&A on Clinical Assessment of MINOCA

Q1. What is the definition of MINOCA?
👉 Myocardial infarction fulfilling universal MI criteria, but with ≤50% stenosis on coronary angiography.

---

Q2. How do MINOCA patients usually present?
👉 With classic ACS symptoms: chest pain, dyspnea, diaphoresis, palpitations, or syncope.

---

Q3. What are the key ECG findings in MINOCA?
👉 ST elevation/depression, T-wave inversion, or new LBBB—similar to obstructive MI.

---

Q4. What is the first step in management when MINOCA is suspected?
👉 Treat initially as ACS until angiography excludes obstructive CAD.

---

Q5. Why is MINOCA called a “working diagnosis”?
👉 Because the angiogram excludes obstructive CAD, but further workup is required to identify the exact cause of myocardial injury.

---

Q6. What non-ischemic conditions can mimic MINOCA?
👉 Myocarditis, Takotsubo cardiomyopathy, pulmonary embolism, sepsis, tachyarrhythmia.

---

Q7. Which advanced imaging modality is most useful to distinguish MINOCA etiologies?
👉 Cardiac MRI (CMR) – helps differentiate infarction from myocarditis or Takotsubo.

---

Q8. What intravascular imaging tools help detect plaque rupture or SCAD?
👉 IVUS (Intravascular Ultrasound) and OCT (Optical Coherence Tomography).

---

Q9. How can coronary vasospasm be diagnosed?
👉 By provocative testing with acetylcholine or ergonovine during angiography.

---

Q10. What bedside principle should guide clinical assessment of MINOCA?
👉 Always rule out systemic causes of troponin elevation, confirm ischemia, and use multimodality imaging to identify the mechanism.

---

---